Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ PASC 14% Improvement Relative Risk Favipiravir  Lokanuwatsatien et al.  EARLY TREATMENT Is early treatment with favipiravir beneficial for COVID-19? Prospective study of 802 patients in Thailand (Sep 2021 - Mar 2022) Lower PASC with favipiravir (not stat. sig., p=0.34) c19early.org Lokanuwatsatien et al., Frontiers in P.., May 2023 Favors favipiravir Favors control

Prevalence and associating factors of long COVID in pediatric patients during the Delta and the Omicron variants

Lokanuwatsatien et al., Frontiers in Pediatrics, doi:10.3389/fped.2023.1127582
May 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Prospective analysis of 802 COVID-19 pediatric patients in Thailand, showing no significant difference in long COVID with favipiravir treatment in unadjusted results.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of PASC, 14.0% lower, OR 0.86, p = 0.34, treatment 400, control 402, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lokanuwatsatien et al., 24 May 2023, prospective, Thailand, peer-reviewed, 8 authors, study period September 2021 - March 2022. Contact: pichaya_t@tu.ac.th.
This PaperFavipiravirAll
Prevalence and associating factors of long COVID in pediatric patients during the Delta and the Omicron variants
Tananya Lokanuwatsatien, Araya Satdhabudha, Auchara Tangsathapornpong, Pornumpa Bunjoungmanee, Phakatip Sinlapamongkolkul, Chanapai Chaiyakulsil, Paskorn Sritipsukho, Pichaya Tantiyavarong
Frontiers in Pediatrics, doi:10.3389/fped.2023.1127582
Introduction: The number of pediatric COVID-19 infections is increasing; however, the data on long COVID conditions in children is still limited. Our study aimed to find the prevalence of long COVID in children during the Delta and Omicron waves, as well as associated factors. Methods: A single-center prospective cohort study was conducted. We included 802 RT-PCR-confirmed COVID-19 pediatric patients in the Delta and Omicron periods. Long COVID was defined as having symptoms for ≥3 months after infection. Parents and/or patients were interviewed by phone. Multivariable logistic regression was performed to find associated factors with long COVID. Results: The overall prevalence of long COVID was 30.2%. The Delta period had more prevalence than the Omicron (36.3% vs. 23.9%). Common symptoms for patients 0-3 years' old were loss of appetite, rhinorrhea, and nasal congestion. Conversely, patients 3-18 years' old had hair loss, dyspnea on exertion, rhinorrhea, and nasal congestion. However, there was no significant negative impact on daily life. Most symptoms improved after a 6-month follow-up. Factors associated with long COVID-19 conditions were infection during the Omicron period (adjusted OR: 0.54; 95% CI: 0.39-0.74, P < 0.001), fever (adjusted OR: 1.49, 95% CI: 1.01-2.20, P = 0.04) and rhinorrhea (adjusted OR: 1.47, 95% CI: 1.06-2.02, P = 0.02). Conclusion: Infection during the Omicron wave has a lower prevalence of long COVID. The prognosis is often favorable, and most symptoms gradually become less. However, pediatricians may schedule appointments to surveil long COVID in children with fever or rhinorrhea as an initial symptom.
Ethics statement The studies involving human participants were reviewed and approved by The Human Research Ethics Committee of Thammasat University No 1 (Faculty of Medicine). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin. Author contributions All authors made substantial contributions to the study and manuscript and met the criteria for authorship defined in the author instruction: TL designed the study, collected data, interpreted the results, drafted and revised the manuscript, and approved the final version of the manuscript. AS designed the study, collected data, interpreted the results, revised the manuscript, and approved the final version of the manuscript. AT designed the study, interpreted the results, revised the manuscript, and approved the final version of the manuscript. PB designed the study, interpreted the results, revised the manuscript, and approved the final version of the manuscript. PSi designed the study, collected data, interpreted the results, revised the manuscript, and approved the final version of the manuscript. CC collected data, designed the study, interpreted the results, revised the manuscript, and approved the final version of the manuscript. PSr designed the study, collected data, interpreted the results, revised the manuscript, and approved the final version of the manuscript. PT designed the study, analyzed data, interpreted the results, drafted and revised the..
References
Afrin, Weinstock, Molderings, COVID-19 hyperinflammation and post-COVID-19 illness may be rooted in mast cell activation syndrome, Int J Infect Dis, doi:10.1016/j.ijid.2020.09.016
Borch, Holm, Knudsen, Ellermann-Eriksen, Hagstroem, Long COVID symptoms and duration in SARS-CoV-2 positive children -a nationwide cohort study
Buonsenso, Morello, Mariani, Rose, Mastrantoni et al., Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC global follow-up protocol: a prospective cohort study, Acta Paediatr, doi:10.1183/13993003.01341-2021
Buonsenso, Munblit, Rose, Sinatti, Ricchiuto et al., Preliminary evidence on long COVID in children, Acta Paediatr, doi:10.1111/apa.15870
Byambasuren, Stehlik, Clark, Alcorn, Glasziou, Effect of COVID-19 vaccination on long COVID: systematic review, BMJ Med, doi:10.1136/bmjmed-2022-000385
Clements, Joseph, Koukounaras, UK NICE guidelines for EVAR: cost implications for post-COVID Australian public health, J Vasc Interv Radiol, doi:10.1007/s00270-021-02832-2
Harris, Taylor, Minor, Elliott, Fernandez et al., The REDCap consortium: building an international community of software platform partners, J Biomed Inform, doi:10.1016/j.jbi.2019.103208
Harris, Taylor, Thielke, Payne, Gonzalez et al., Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform, doi:10.1016/j.jbi.2008.08.010
Khemiri, Ayouni, Triki, Haddad-Boubaker, SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and omicron (B.1.1.529) variants era, Virol J, doi:10.1186/s12985-022-01873-4
Lokanuwatsatien, None
Lopez-Leon, Wegman-Ostrosky, Del Valle, Perelman, Sepulveda et al., Long-COVID in children and adolescents: a systematic review and meta-analyses, Sci Rep, doi:10.1038/s41598-022-13495-5
Molteni, Sudre, Canas, Bhopal, Hughes et al., Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health, Eur J Pediatr, doi:10.1016/S2352-4642(21)00198-X
Notarte, Catahay, Velasco, Pastrana, Ver et al., Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review, EClinicalMedicine, doi:10.1016/j.eclinm.2022.101624
Satdhabudha, Chaiyakulsil, Sritipsukho, Sinlapamongkolkul, Chaumrattanakul et al., Epidemiological and clinical characteristics of pediatric COVID-19 in the tertiary care system in Thailand: comparative Delta and pre-Delta era, Mediterr J Hematol Infect Dis, doi:10.4084/MJHID.2022.044
Say, Crawford, Mcnab, Wurzel, Steer et al., Post-acute COVID-19 outcomes in children with mild and asymptomatic disease, Lancet Child Adolesc Health, doi:10.1016/S2352-4642(21)00124-3
She, Liu, Liu, COVID-19 epidemic: disease characteristics in children, J Med Virol, doi:10.1002/jmv.25807
Smane, Roge, Pucuka, Pavare, Clinical features of pediatric post-acute COVID-19: a descriptive retrospective follow-up study, Ital J Pediatr, doi:10.1186/s13052-021-01127-z
Thomson, Children with long COVID, New Sci, doi:10.1016/S0262-4079(21)00303-1
Torjesen, COVID-19: omicron variant is linked to steep rise in hospital admissions of very young children, Br Med J, doi:10.1136/bmj.—o110
Wise, COVID-19: long COVID risk is lower with omicron than delta, researchers find, Br Med J, doi:10.1136/bmj.o1500
Wise, Long, one in seven children may still have symptoms 15 weeks after infection, data show, Br Med J, doi:10.1136/bmj.n2157
{ 'DOI': '10.3389/fped.2023.1127582', 'ISSN': ['2296-2360'], 'URL': 'http://dx.doi.org/10.3389/fped.2023.1127582', 'abstract': '<jats:sec><jats:title>Introduction</jats:title><jats:p>The number of pediatric COVID-19 ' 'infections is increasing; however, the data on long COVID conditions in children is still ' 'limited. Our study aimed to find the prevalence of long COVID in children during the Delta ' 'and Omicron waves, as well as associated ' 'factors.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A single-center ' 'prospective cohort study was conducted. We included 802 RT-PCR-confirmed COVID-19 pediatric ' 'patients in the Delta and Omicron periods. Long COVID was defined as having symptoms for ≥3 ' 'months after infection. Parents and/or patients were interviewed by phone. Multivariable ' 'logistic regression was performed to find associated factors with long ' 'COVID.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The overall ' 'prevalence of long COVID was 30.2%. The Delta period had more prevalence than the Omicron ' '(36.3% vs. 23.9%). Common symptoms for patients 0–3 years’ old were loss of appetite, ' 'rhinorrhea, and nasal congestion. Conversely, patients 3–18 years’ old had hair loss, dyspnea ' 'on exertion, rhinorrhea, and nasal congestion. However, there was no significant negative ' 'impact on daily life. Most symptoms improved after a 6-month follow-up. Factors associated ' 'with long COVID-19 conditions were infection during the Omicron period (adjusted OR: 0.54; ' '95% CI: 0.39–0.74, <jats:italic>P</jats:italic>\u2009&amp;lt;\u20090.001), fever (adjusted ' 'OR: 1.49, 95% CI: 1.01–2.20, <jats:italic>P</jats:italic>\u2009=\u20090.04) and rhinorrhea ' '(adjusted OR: 1.47, 95% CI: 1.06–2.02, <jats:italic>P\u2009</jats:italic>=\u2009' '0.02).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Infection ' 'during the Omicron wave has a lower prevalence of long COVID. The prognosis is often ' 'favorable, and most symptoms gradually become less. However, pediatricians may schedule ' 'appointments to surveil long COVID in children with fever or rhinorrhea as an initial ' 'symptom.</jats:p></jats:sec>', 'alternative-id': ['10.3389/fped.2023.1127582'], 'author': [ {'affiliation': [], 'family': 'Lokanuwatsatien', 'given': 'Tananya', 'sequence': 'first'}, {'affiliation': [], 'family': 'Satdhabudha', 'given': 'Araya', 'sequence': 'additional'}, { 'affiliation': [], 'family': 'Tangsathapornpong', 'given': 'Auchara', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bunjoungmanee', 'given': 'Pornumpa', 'sequence': 'additional'}, { 'affiliation': [], 'family': 'Sinlapamongkolkul', 'given': 'Phakatip', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Chaiyakulsil', 'given': 'Chanapai', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sritipsukho', 'given': 'Paskorn', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Tantiyavarong', 'given': 'Pichaya', 'sequence': 'additional'}], 'container-title': 'Frontiers in Pediatrics', 'container-title-short': 'Front. Pediatr.', 'content-domain': {'crossmark-restriction': True, 'domain': ['frontiersin.org']}, 'created': {'date-parts': [[2023, 5, 24]], 'date-time': '2023-05-24T05:45:00Z', 'timestamp': 1684907100000}, 'deposited': { 'date-parts': [[2023, 5, 24]], 'date-time': '2023-05-24T05:45:03Z', 'timestamp': 1684907103000}, 'funder': [{'award': ['\xa0']}, {'award': ['\xa0']}], 'indexed': {'date-parts': [[2023, 5, 25]], 'date-time': '2023-05-25T04:06:39Z', 'timestamp': 1684987599533}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2023, 5, 24]]}, 'license': [ { 'URL': 'https://creativecommons.org/licenses/by/4.0/', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2023, 5, 24]], 'date-time': '2023-05-24T00:00:00Z', 'timestamp': 1684886400000}}], 'link': [ { 'URL': 'https://www.frontiersin.org/articles/10.3389/fped.2023.1127582/full', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '1965', 'original-title': [], 'prefix': '10.3389', 'published': {'date-parts': [[2023, 5, 24]]}, 'published-online': {'date-parts': [[2023, 5, 24]]}, 'publisher': 'Frontiers Media SA', 'reference': [ { 'DOI': '10.1002/jmv.25807', 'article-title': 'COVID-19 epidemic: disease characteristics in children', 'author': 'She', 'doi-asserted-by': 'publisher', 'first-page': '747', 'journal-title': 'J Med Virol', 'key': 'B1', 'volume': '92', 'year': '2020'}, { 'DOI': '10.1016/S2352-4642(21)00124-3', 'article-title': 'Post-acute COVID-19 outcomes in children with mild and asymptomatic ' 'disease', 'author': 'Say', 'doi-asserted-by': 'publisher', 'first-page': 'e22', 'journal-title': 'Lancet Child Adolesc Health', 'key': 'B2', 'volume': '5', 'year': '2021'}, { 'DOI': '10.4084/MJHID.2022.044', 'article-title': 'Epidemiological and clinical characteristics of pediatric COVID-19 in ' 'the tertiary care system in Thailand: comparative Delta and pre-Delta ' 'era', 'author': 'Satdhabudha', 'doi-asserted-by': 'publisher', 'first-page': 'e2022044', 'journal-title': 'Mediterr J Hematol Infect Dis', 'key': 'B3', 'volume': '14', 'year': '2022'}, { 'DOI': '10.1186/s12985-022-01873-4', 'article-title': 'SARS-CoV-2 infection in pediatric population before and during the ' 'Delta (B.1.617.2) and omicron (B.1.1.529) variants era', 'author': 'Khemiri', 'doi-asserted-by': 'publisher', 'first-page': '144', 'journal-title': 'Virol J', 'key': 'B4', 'volume': '19', 'year': '2022'}, { 'DOI': '10.1136/bmj.o110', 'article-title': 'COVID-19: omicron variant is linked to steep rise in hospital ' 'admissions of very young children', 'author': 'Torjesen', 'doi-asserted-by': 'publisher', 'first-page': 'o110', 'journal-title': 'Br Med J', 'key': 'B5', 'volume': '376', 'year': '2022'}, { 'DOI': '10.1007/s00270-021-02832-2', 'article-title': 'UK NICE guidelines for EVAR: cost implications for post-COVID ' 'Australian public health', 'author': 'Clements', 'doi-asserted-by': 'publisher', 'first-page': '1286', 'journal-title': 'J Vasc Interv Radiol', 'key': 'B6', 'volume': '44', 'year': '2021'}, { 'DOI': '10.1186/s13052-021-01127-z', 'article-title': 'Clinical features of pediatric post-acute COVID-19: a descriptive ' 'retrospective follow-up study', 'author': 'Smane', 'doi-asserted-by': 'publisher', 'first-page': '177', 'journal-title': 'Ital J Pediatr', 'key': 'B7', 'volume': '47', 'year': '2021'}, { 'DOI': '10.1016/S0262-4079(21)00303-1', 'article-title': 'Children with long COVID', 'author': 'Thomson', 'doi-asserted-by': 'publisher', 'first-page': '10', 'journal-title': 'New Sci', 'key': 'B8', 'volume': '249', 'year': '2021'}, { 'DOI': '10.1111/apa.15870', 'article-title': 'Preliminary evidence on long COVID in children', 'author': 'Buonsenso', 'doi-asserted-by': 'publisher', 'first-page': '2208', 'journal-title': 'Acta Paediatr', 'key': 'B9', 'volume': '110', 'year': '2021'}, {'key': 'B10', 'year': ''}, {'key': 'B11', 'year': ''}, {'key': 'B12', 'year': ''}, {'key': 'B13', 'year': ''}, { 'DOI': '10.1016/j.jbi.2019.103208', 'article-title': 'The REDCap consortium: building an international community of software ' 'platform partners', 'author': 'Harris', 'doi-asserted-by': 'publisher', 'first-page': '103208', 'journal-title': 'J Biomed Inform', 'key': 'B14', 'volume': '95', 'year': '2019'}, { 'DOI': '10.1016/j.jbi.2008.08.010', 'article-title': 'Research electronic data capture (REDCap)–a metadata-driven methodology ' 'and workflow process for providing translational research informatics ' 'support', 'author': 'Harris', 'doi-asserted-by': 'publisher', 'first-page': '377', 'journal-title': 'J Biomed Inform', 'key': 'B15', 'volume': '42', 'year': '2009'}, { 'DOI': '10.1038/s41598-022-13495-5', 'article-title': 'Long-COVID in children and adolescents: a systematic review and ' 'meta-analyses', 'author': 'Lopez-Leon', 'doi-asserted-by': 'publisher', 'first-page': '9950', 'journal-title': 'Sci Rep', 'key': 'B16', 'volume': '12', 'year': '2022'}, { 'DOI': '10.1136/bmj.o1500', 'article-title': 'COVID-19: long COVID risk is lower with omicron than delta, researchers ' 'find', 'author': 'Wise', 'doi-asserted-by': 'publisher', 'first-page': 'o1500', 'journal-title': 'Br Med J', 'key': 'B17', 'volume': '377', 'year': '2022'}, { 'DOI': '10.1111/apa.16764', 'article-title': 'Risk of long COVID in children infected with omicron or pre-omicron ' 'SARS-CoV-2 variants', 'author': 'Buonsenso', 'doi-asserted-by': 'publisher', 'first-page': '1284', 'journal-title': 'Acta Paediatr', 'key': 'B18', 'volume': '112', 'year': '2023'}, { 'DOI': '10.1183/13993003.01341-2021', 'article-title': 'Risk factors for post-COVID-19 condition in previously hospitalised ' 'children using the ISARIC global follow-up protocol: a prospective ' 'cohort study', 'author': 'Osmanov', 'doi-asserted-by': 'publisher', 'first-page': '2101341', 'journal-title': 'Eur Respir J', 'key': 'B19', 'volume': '59', 'year': '2022'}, { 'DOI': '10.1136/bmj.n2157', 'article-title': 'Long COVID: one in seven children may still have symptoms 15 weeks ' 'after infection, data show', 'author': 'Wise', 'doi-asserted-by': 'publisher', 'first-page': 'n2157', 'journal-title': 'Br Med J', 'key': 'B20', 'volume': '374', 'year': '2021'}, { 'DOI': '10.1016/j.ijid.2020.09.016', 'article-title': 'COVID-19 hyperinflammation and post-COVID-19 illness may be rooted in ' 'mast cell activation syndrome', 'author': 'Afrin', 'doi-asserted-by': 'publisher', 'first-page': '327', 'journal-title': 'Int J Infect Dis', 'key': 'B21', 'volume': '100', 'year': '2020'}, { 'DOI': '10.1007/s00431-021-04345-z', 'article-title': 'Long COVID symptoms and duration in SARS-CoV-2 positive children - a ' 'nationwide cohort study', 'author': 'Borch', 'doi-asserted-by': 'publisher', 'first-page': '1597', 'journal-title': 'Eur J Pediatr', 'key': 'B22', 'volume': '181', 'year': '2022'}, { 'DOI': '10.1016/S2352-4642(21)00198-X', 'article-title': 'Illness duration and symptom profile in symptomatic UK school-aged ' 'children tested for SARS-CoV-2', 'author': 'Molteni', 'doi-asserted-by': 'publisher', 'first-page': '708', 'journal-title': 'Lancet Child Adolesc Health', 'key': 'B23', 'volume': '5', 'year': '2021'}, { 'DOI': '10.1016/j.eclinm.2022.101624', 'article-title': 'Impact of COVID-19 vaccination on the risk of developing long-COVID and ' 'on existing long-COVID symptoms: a systematic review', 'author': 'Notarte', 'doi-asserted-by': 'publisher', 'first-page': '101624', 'journal-title': 'EClinicalMedicine', 'key': 'B24', 'volume': '53', 'year': '2022'}, { 'DOI': '10.1136/bmjmed-2022-000385', 'article-title': 'Effect of COVID-19 vaccination on long COVID: systematic review', 'author': 'Byambasuren', 'doi-asserted-by': 'publisher', 'first-page': 'e000385', 'journal-title': 'BMJ Med', 'key': 'B25', 'volume': '2', 'year': '2023'}], 'reference-count': 25, 'references-count': 25, 'relation': {}, 'resource': {'primary': {'URL': 'https://www.frontiersin.org/articles/10.3389/fped.2023.1127582/full'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Pediatrics, Perinatology and Child Health'], 'subtitle': [], 'title': 'Prevalence and associating factors of long COVID in pediatric patients during the Delta and the ' 'Omicron variants', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.3389/crossmark-policy', 'volume': '11'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit